Biotech-компания ImmunityBio выросла на 22% благодаря сильным прогнозам по препарату от рака мочевого пузыря, акции Coupang поднялись после повышения рейтинга Deutsche Bank
На фондовом рынке произошло несколько значительных изменений.
ImmunityBio
Precio: 1.67Empresa y modelo de negocio
ImmunityBio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. Its core products include novel therapies that leverage the immune system to target tumors and viral infections. The company operates primarily in the healthcare sector, with major revenue sources stemming from research collaborations and potential future product sales. ImmunityBio is currently in the clinical trial phase for several of its therapies, which are aimed at addressing unmet medical needs in oncology and infectious disease treatment.
Perfil de inversión
The investment profile of ImmunityBio suggests it may be more suitable for growth investors, given its focus on innovative therapies and potential future market opportunities. However, the company's significant risks and recent financial performance indicate a high level of uncertainty. Investors should consider their risk tolerance and investment strategy when evaluating this stock.
Métricas fundamentales
- EPS (TTM) — ganancias por acción de los últimos 12 meses, $
- -0.58 Riesgo
- Ingresos QoQ — crecimiento trimestral de ingresos
- -100.0% ↓
- Sorpresa EPS
- -16.7% peor de lo esperado
- Volatilidad 20d
- 5.4% normal
Datos FMP / FinFeed actualizados:
2026-06-10
Recomendación: Vender
Potencial: 20
Riesgo: 80
Actualizado: 2026-06-11 05:21
Cómo funciona la recomendación
Por qué la IA piensa así:
Weak fundamentals and negative momentum indicate high risk.
Seguir en portafolio
Gráfico de precio
Recomendación IA
Pronóstico de analista
Evento de calendario
Señal positiva
Señal negativa
Neutral / actualización
Mantener / informativo
B My buy
S My sell
Cambios de recomendación IA
| Fecha | Antes | Después | Razón |
|---|---|---|---|
| 2026-05-08 15:23 | — | Vender | scenario_deterioration |
| 2026-05-08 05:19 | Vender | Vender | scenario_deterioration |
| 2026-04-17 02:46 | Mantener | Vender | Компания демонстрирует высокую волатильность и отрицательные финансовые показатели, что указывает на значительные риски. Однако недавний рост на 51.80% за 120 дней может свидетельствовать о потенциальных возможностях для |
Pronósticos de analistas
| Fecha | Analista | Acción | Objetivo | Precio entonces |
|---|---|---|---|---|
| 2026-06-08 10:30 | Raymond James | Actualizar | — → 5 | 1.82 |
| 2025-10-17 10:19 | Leerink Partners | Actualizar | — → 2 | 0.8455 |